Skip to main content

Month: February 2026

Transocean Ltd. Reports Fourth Quarter and Full Year 2025 Results

STEINHAUSEN, Switzerland, Feb. 19, 2026 (GLOBE NEWSWIRE) — Transocean Ltd. (NYSE: RIG) today reported financial results for the fourth quarter and full year of 2025. The Company will hold a conference call and webcast at 9 a.m. EST, 3 p.m. CET, on Friday, February 20, 2026, to discuss the results, with participation details included in this release. In addition, supplemental slides have been posted to the Investors section of the Company’s website at www.deepwater.com. 2025 KEY POINTSOperating revenues were $3.965 billion, up 13% from $3.524 billion in 2024. Revenue efficiency(1) was 96.5%, up from 94.5%. Net loss attributable to controlling interest was $2.915 billion, $3.04 per diluted share. Adjusted EBITDA of $1.37 billion, up from $1.148 billion or 19%. Cash flows from operations were $749 million, up $302 million or 68%. Free...

Continue reading

FY 2025 Results: Strong Commercial Growth, Focused Pipeline Investment

MELBOURNE, Australia and INDIANAPOLIS, Feb. 20, 2026 (GLOBE NEWSWIRE) — Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) today announces its financial results for the year ended December 31, 2025. FY 2025 key results1 Group performance2: Double-digit revenue growth and positive adjusted operating cash flowRevenue of US$803.8 million, up by 56%3 and achieving upsized full year guidance4. US$157.1 million invested in research and development (R&D) product development for late-stage therapeutics and precision medicine pipeline assets5, in line with stated FY 2025 guidance. Adjusted EBITDA6 of US$39.5 million, reflective of increased operating expenditure driven by strategic acquisitions, investment in commercial infrastructure and research and development (R&D). A non-material loss before tax...

Continue reading

Imperial Provides Update on Red Chris 2025 Production and Production Guidance for 2026

VANCOUVER, British Columbia, Feb. 19, 2026 (GLOBE NEWSWIRE) — Imperial Metals Corporation (the “Company” or “Imperial”) (TSX:III) reports that 2025 metal production from Red Chris (100% basis) was 93,101,213 pounds of copper and 92,429 ounces of gold, up from 85,320,618 pounds of copper and 59,811 ounces of gold in 2024, on higher grades for both metals and higher recovery for gold. Red Chris exceeded its 2025 production guidance of 88 million pounds of copper and 86,000 ounces of gold for the calendar year 2025. Imperial’s 30% share of Red Chris mine production for 2025 was 27,930,364 pounds of copper up from 25,596,185 pounds copper in 2024 and 27,729 ounces of gold up from 17,943 ounces gold in 2024. The Red Chris feasibility study for a block cave expansion operation is advancing, as are permitting activities to support the...

Continue reading

D. Boral Acquisition I Corp. Announces the Separate Trading of its Class A Ordinary Shares and Warrants Commencing February 25, 2026

New York, NY, Feb. 19, 2026 (GLOBE NEWSWIRE) — D. Boral Acquisition I Corp. (the “Company”) today announced that, commencing February 25, 2026, holders of the units sold in the Company’s initial public offering may elect to separately trade the Company’s Class A ordinary shares and warrants included in the units. No fractional warrants will be issued upon separation of the units and only whole warrants will trade. The Class A ordinary shares and warrants that are separated will trade on The Nasdaq Global Market under the symbols “DBCA” and “DBCAW,” respectively. Those units not separated will continue to trade on The Nasdaq Global Market under the symbol “DBCAU.” Holders of units will need to have their brokers contact Continental Stock Transfer & Trust Company, the Company’s transfer agent, in order to separate the units...

Continue reading

Altisource Portfolio Solutions S.A. Schedules Fourth Quarter 2025 Conference Call

LUXEMBOURG, Feb. 19, 2026 (GLOBE NEWSWIRE) — On Wednesday, March 4, 2026, Altisource Portfolio Solutions S.A. (“Altisource”) (NASDAQ: ASPS) will report earnings for the fourth quarter 2025. A press release and presentation will be available on Altisource’s website in the Investor Relations section. Altisource will also host a conference call at 8:30 a.m. EST on the same day to discuss its fourth quarter 2025 results. A link to the live audio webcast will be available on Altisource’s website in the Investor Relations section. Those who want to listen to the call should go to the website at least fifteen minutes prior to the call to register, download and install any necessary audio software. A replay of the conference call will be available via the website approximately two hours after the conclusion of the call and will remain...

Continue reading

Sienna Reports Fourth Quarter 2025 Financial Results and Continues Platform Growth

MARKHAM, Ontario, Feb. 19, 2026 (GLOBE NEWSWIRE) — Sienna Senior Living Inc. (“Sienna” or the “Company”) (TSX: SIA) today announced its financial results for the three and twelve months ended December 31, 2025. HighlightsAverage Same Property Occupancy in retirement segment up 180 basis points (“bps”) year over year, to 94.7% in Q4 2025, further increasing to 95.2% in January 2026 Revenue exceeds $1.0 billion in 2025, up 15.0% year-over-year Same Property Net Operating Income (“NOI”), excluding One-Time Items, up 10.1% year-over-year to $47.4 million in Q4 2025Retirement Segment up 15.4% year-over-year in Q4 2025 Long-Term Care (“LTC”) Segment up 5.6% year-over year in Q4 2025Adjusted Funds from Operations (“AFFO”), excluding One-Time Items, increased by 19.8% year-over-year, or by 3.9% on a per share basis, in Q4 2025 AFFO...

Continue reading

Prospective Validation Study in JAAD Demonstrates Castle Biosciences’ AdvanceAD-Tx™ Test Identifies Patients More Likely to Achieve Faster and Deeper Responses with JAK Inhibitor Therapy in Moderate-to-Severe Atopic Dermatitis

Study data show that AdvanceAD-Tx can stratify patients by molecular profile identifying those more likely to achieve near-clear skin (EASI-90), faster time to response and meaningful patient-reported benefits when treated with JAK inhibitor therapy compared to a Th2-targeted therapy FRIENDSWOOD, Texas, Feb. 19, 2026 (GLOBE NEWSWIRE) — Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced the publication of a prospective, multicenter clinical validation study in the Journal of the American Academy of Dermatology (JAAD) demonstrating that its AdvanceAD-Tx test can identify patients with moderate-to-severe atopic dermatitis (AD) who are significantly more likely to achieve greater and faster clinical responses when treated with a Janus kinase inhibitor...

Continue reading

VivoPower Announces Leadership Changes

LONDON, Feb. 19, 2026 (GLOBE NEWSWIRE) — VivoPower International PLC (Nasdaq: VVPR) (“VivoPower” or the “Company”), a leading B Corp-certified global developer and owner of powered land and data center infrastructure for AI compute applications, today announced changes to its executive leadership team. As part of the Company’s strategic focus on powered land and data center infrastructure — reflected in its recently announced acquisition of 291MW of powered sites in Finland, the securing of site and power access for a 25MW data center platform in the United Arab Emirates, and the successful completion of a $30 million PIPE financing, as well as the proposed acquisition of a 40MW energized Norway data center expected to add approximately $10 million in pro forma EBITDA — and following the transfer of its...

Continue reading

Centerra Gold Reports Fourth Quarter and Full Year 2025 Results; Delivered Robust Annual Production and Beat Cost Guidance; 2026 Outlook Remains Strong as Centerra Executes its Self-Funded Growth Strategy

 This news release contains forward-looking information about expected future events that is subject to risks and assumptions set out in the “Cautionary Statement on Forward-Looking Information” below. All figures are in United States dollars. All production figures reflect payable metal quantities and are on a 100% basis, unless otherwise stated. For references denoted with NG, refer to the “Non-GAAP and Other Financial Measures” disclosure at the end of this news release for a description of these measures. TORONTO, Feb. 19, 2026 (GLOBE NEWSWIRE) — Centerra Gold Inc. (“Centerra” or the “Company”) (TSX: CG and NYSE: CGAU) today reported its fourth quarter and full year 2025 operating and financial results and issued 2026 guidance. President and CEO, Paul Tomory, commented, “In the fourth quarter, we delivered strong production...

Continue reading

Eldorado Gold Delivers Strong 2025 Full Year and Fourth Quarter Financial and Operational Results; Significant Free Cash Flow Excluding Skouries and Increased Cash Generated From Operating Activities

(All amounts expressed in U.S. dollars unless otherwise noted) VANCOUVER, British Columbia, Feb. 19, 2026 (GLOBE NEWSWIRE) — Eldorado Gold Corporation (“Eldorado” or the “Company”) today reports the Company’s financial and operational results for the fourth quarter and year ended December 31, 2025. For further information please see the Company’s Consolidated Financial Statements and Management’s Discussion and Analysis (“MD&A”) filed on SEDAR+ at www.sedarplus.com under the Company’s profile. Q4 2025 and Full-Year Summary OperationsGold production: 123,416 ounces in Q4 2025. Full-year 2025 production of 488,268 ounces, achieving the higher-end of 2025 production guidance. Gold sales: 126,923 ounces in Q4 2025 at an average realized gold price per ounce sold(1) of $4,251, resulting in 491,204 ounces sold in 2025 at...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.